Aliases & Classifications for Retinal Disease

Aliases & Descriptions for Retinal Disease:

Name: Retinal Disease 12 14
Retinal Diseases 42 69
Retinal Disorders 41

Classifications:



External Ids:

Disease Ontology 12 DOID:5679
ICD10 33 H35.9 H36 H35.8
ICD9CM 35 362.9
MeSH 42 D012164
UMLS 69 C0035309

Summaries for Retinal Disease

MedlinePlus : 41 the retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. in the center of this nerve tissue is the macula. it provides the sharp, central vision needed for reading, driving and seeing fine detail. retinal disorders affect this vital tissue. they can affect your vision, and some can be serious enough to cause blindness. examples are macular degeneration - a disease that destroys your sharp, central vision diabetic eye disease retinal detachment - a medical emergency, when the retina is pulled away from the back of the eye retinoblastoma - cancer of the retina. it is most common in young children. macular pucker - scar tissue on the macula macular hole - a small break in the macula that usually happens to people over 60 floaters - cobwebs or specks in your field of vision nih: national eye institute

MalaCards based summary : Retinal Disease, also known as retinal diseases, is related to choriodal dystrophy, central areolar 2 and retinal degeneration, and has symptoms including eye manifestations An important gene associated with Retinal Disease is RHO (Rhodopsin), and among its related pathways/superpathways are Phototransduction and Metabolism of fat-soluble vitamins. The drugs Nitric Oxide and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and brain, and related phenotypes are nervous system and pigmentation

Disease Ontology : 12 An eye disease that is located in the retina.

Related Diseases for Retinal Disease

Diseases related to Retinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
id Related Disease Score Top Affiliating Genes
1 choriodal dystrophy, central areolar 2 31.1 PRPH2 RHO
2 retinal degeneration 10.8
3 leber congenital amaurosis 10.8
4 aland island eye disease 10.6
5 retinitis 10.6
6 night blindness, congenital stationary , 1e, autosomal recessive 10.6
7 night blindness, congenital stationary , 1a, x-linked 10.6
8 usher syndrome, type 2a 10.6
9 macular dystrophy, vitelliform, 5 10.5
10 macular dystrophy, vitelliform, 3 10.5
11 macular dystrophy, vitelliform, 4 10.5
12 bradyopsia 10.5
13 cone dystrophy 10.5
14 senior-loken syndrome 4 10.4
15 stargardt disease 1 10.4
16 senior-loken syndrome 7 10.4
17 senior-loken syndrome-1 10.4
18 oguchi disease-1 10.4
19 night blindness, congenital stationary, autosomal dominant 3 10.4
20 night blindness, congenital stationary, type 1g 10.4
21 night blindness, congenital stationary, autosomal dominant 1 10.4
22 senior-loken syndrome 5 10.4
23 night blindness, congenital stationary, autosomal dominant 2 10.4
24 senior-loken syndrome 8 10.4
25 night blindness, congenital stationary , 1f, autosomal recessive 10.4
26 night blindness, congenital stationary , 1b, autosomal recessive 10.4
27 cone-rod synaptic disorder, congenital nonprogressive 10.4
28 senior-loken syndrome 6 10.4
29 oguchi disease-2 10.4
30 night blindness, congenital stationary , 1c, autosomal recessive 10.4
31 night blindness, congenital stationary , 1d, autosomal recessive 10.4
32 pseudoxanthoma elasticum 10.4
33 ethylmalonic encephalopathy 10.4
34 night blindness, congenital stationary , 2a, x-linked 10.4
35 cone-rod dystropy, x-linked, 3 10.4
36 congenital stationary night blindness 1h 10.4
37 x-linked congenital stationary night blindness 10.4
38 senior-loken syndrome 9 10.4
39 macular degeneration, age-related, 2 10.4 ABCA4 CACNA1F
40 branchial cleft anomalies branchial cysts, included 10.4 RHO USH2A
41 cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia 10.4 GUCY2D RPE65
42 anophthalmia-esophageal atresia-genital abnormalities syndrome 10.4 AIPL1 GUCY2D RPE65
43 syne2-related emery-dreifuss muscular dystrophy 10.4 ABCA4 CNGB3
44 congenital leptin deficiency 10.4 PDE6B RHO
45 refractive error 10.4 GUCA1A GUCY2D PRPH2
46 restless legs syndrome 6 10.4 BEST1 PRPH2
47 proximal myopathy and ophthalmoplegia 10.4 GUCA1A GUCY2D
48 neonatal abstinence syndrome 10.4 GUCA1A GUCY2D PRPH2
49 bartholin's duct cyst 10.4 CRB1 GUCY2D RHO
50 brugada syndrome 6 10.4 BEST1 RPGR

Graphical network of the top 20 diseases related to Retinal Disease:



Diseases related to Retinal Disease

Symptoms & Phenotypes for Retinal Disease

UMLS symptoms related to Retinal Disease:


eye manifestations

MGI Mouse Phenotypes related to Retinal Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.09 ABCA4 AIPL1 CACNA1F CFH CNGB3 CRB1
2 pigmentation MP:0001186 9.77 RPE65 RPGR RS1 ABCA4 BEST1 CFH
3 vision/eye MP:0005391 9.6 AIPL1 BEST1 CACNA1F CFH CNGB3 CRB1

Drugs & Therapeutics for Retinal Disease

Drugs for Retinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 847)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1 10102-43-9 145068
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4
Fenofibrate Approved Phase 4,Phase 3,Phase 2 49562-28-9 3339
5
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
6
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
7
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
8
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2 2068-78-2, 57-22-7 5978
10
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
11
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
12
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
13
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
14
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
15
Diclofenac Approved, Vet_approved Phase 4,Phase 1 15307-86-5 3033
16
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2 85721-33-1 2764
17
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1 113852-37-2 60613
18
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
19
Glimepiride Approved Phase 4 93479-97-1 3476
20
Metformin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 657-24-9 14219 4091
21
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1 1952-01-7, 52-01-7 5833
22
Eplerenone Approved Phase 4,Phase 3,Phase 2 107724-20-9 150310 443872
23
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
24
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
25
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 378-44-9 9782
26
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2 170277-31-3
27
Timolol Approved Phase 4,Phase 2,Phase 3 26839-75-8 33624 5478
28
Ephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 299-42-3 9294
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
31
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
32
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
33
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2 59-66-5 1986
34
Glatiramer Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 147245-92-9 3081884
35
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1 74103-06-3, 66635-83-4 3826
36
Minocycline Approved, Investigational Phase 4,Phase 2,Phase 1 10118-90-8 5281021
37
Dorzolamide Approved Phase 4,Phase 2,Phase 3 120279-96-1 3154 5284549
38
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129497-78-5
39
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1 63585-09-1, 4428-95-9 3415
40
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 124-94-7 31307
41
Vildagliptin Approved, Investigational Phase 4,Phase 3 274901-16-5 6918537
42
Liraglutide Approved Phase 4,Phase 3 204656-20-2
43
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
44
Cefazolin Approved Phase 4 25953-19-9 656510 33255
45
Latanoprost Approved, Investigational Phase 4,Phase 3 130209-82-4 5282380 5311221
46
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
47
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 90-82-4 7028
48
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
49
Loteprednol Approved Phase 4 82034-46-6, 129260-79-3 444025 9865442
50
Hydroxocobalamin Approved Phase 4,Phase 2 13422-51-0 11953898 5460373 44475014

Interventional clinical trials:

(show top 50) (show all 3193)
id Name Status NCT ID Phase
1 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4
2 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
3 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
4 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4
5 Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Unknown status NCT00634972 Phase 4
6 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4
7 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4
8 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4
9 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4
10 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4
11 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4
12 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
13 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
14 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
15 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
16 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
17 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4
18 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4
19 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
20 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4
21 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
22 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4
23 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4
24 The Endurance 1 Trial Unknown status NCT02297204 Phase 4
25 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4
26 A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Unknown status NCT00354445 Phase 4
27 Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor Unknown status NCT01896284 Phase 4
28 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
29 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4
30 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
31 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4
32 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
33 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4
34 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4
35 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4
36 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4
37 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4
38 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4
39 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4
40 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4
41 Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain Unknown status NCT02324166 Phase 4
42 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
43 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
44 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4
45 Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure Unknown status NCT00796198 Phase 4
46 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4
47 Anesthesia for Retinopathy of Prematurity Completed NCT01955135 Phase 4
48 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4
49 Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients Completed NCT00174824 Phase 4
50 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4

Search NIH Clinical Center for Retinal Disease

Cochrane evidence based reviews: retinal diseases

Genetic Tests for Retinal Disease

Anatomical Context for Retinal Disease

MalaCards organs/tissues related to Retinal Disease:

39
Eye, Retina, Brain, Testes, Endothelial, T Cells, Placenta

The Foundational Model of Anatomy Ontology organs/tissues related to Retinal Disease:

18
The Retina

Publications for Retinal Disease

Articles related to Retinal Disease:

(show top 50) (show all 314)
id Title Authors Year
1
Safety and acceptability of an organic light-emitting diode sleep mask as a potential therapy for retinal disease. ( 27983728 )
2017
2
Minireview: Fibronectin in retinal disease. ( 27798121 )
2017
3
Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. ( 28041643 )
2017
4
Evidence for Telemedicine for Diabetic Retinal Disease. ( 27748634 )
2017
5
Multimodal Imaging in Retinal Disease: A Consensus Definition. ( 26985792 )
2016
6
A computer-assisted method for pathogenicity assessment and genetic reporting of variants stored in the Australian Inherited Retinal Disease Register. ( 26728880 )
2016
7
Intravitreal Steroid Implants in the Management of Retinal Disease and Uveitis. ( 27575764 )
2016
8
Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases. ( 26603570 )
2016
9
Author Response: Comments on Enrichment of Macular Pigment Enhances Contrast Sensitivity in Subjects Free of Retinal Disease: CREST - Report 1. ( 27737465 )
2016
10
The clinical features of retinal disease due to a dominant mutation in RPE65. ( 27307694 )
2016
11
Anti-angiogenic Therapy for Retinal Disease. ( 27783271 )
2016
12
Macromolecular markers in normal human retina and applications to human retinal disease. ( 26769220 )
2016
13
Cell-Based Therapy for Degenerative Retinal Disease. ( 26791247 )
2016
14
Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. ( 27664289 )
2016
15
Enrichment of Macular Pigment Enhances Contrast Sensitivity in Subjects Free of Retinal Disease: Central Retinal Enrichment Supplementation Trials - Report 1. ( 27367585 )
2016
16
Investigation of SLA4A3 as a candidate gene for human retinal disease. ( 27211793 )
2016
17
Whole Genome Sequencing Increases Molecular Diagnostic Yield Compared with Current Diagnostic Testing for Inherited Retinal Disease. ( 26872967 )
2016
18
Wide field of view swept-source optical coherence tomography for peripheral retinal disease. ( 26755643 )
2016
19
Advanced Diagnostic Genetic Testing In Inherited Retinal Disease:Experience from a Single Tertiary Referral Centre in the UK National Health Service. ( 27160483 )
2016
20
Hsp90 as a Potential Therapeutic Target in Retinal Disease. ( 26427407 )
2016
21
Clustered Regularly Interspaced Short Palindromic Repeats: Challenges in Treating Retinal Disease. ( 27488072 )
2016
22
Telemedicine for a General Screening of Retinal Disease Using Nonmydriatic Fundus Cameras in Optometry Centers: Three-Year Results. ( 27228051 )
2016
23
Molecular findings from 537 individuals with inherited retinal disease. ( 27208204 )
2016
24
Optical Coherence Tomography Angiography of Miscellaneous Retinal Disease. ( 27023316 )
2016
25
How Was Your Sleep? New Implications for Obstructive Sleep Apnea in Retinal Disease. ( 26841214 )
2016
26
The Prevalence and Characteristics of Charles Bonnet Syndrome in Turkish Patients with Retinal Disease. ( 27188990 )
2016
27
Comments on Enrichment of Macular Pigment Enhances Contrast Sensitivity in Subjects Free of Retinal Disease: CREST - Report 1. ( 27737464 )
2016
28
Systemic confounders affecting serum measurements of omega-3 and -6 polyunsaturated fatty acids in patients with retinal disease. ( 27596098 )
2016
29
Clinical applications of fundus autofluorescence in retinal disease. ( 27847630 )
2016
30
Comparative sequence analyses of rhodopsin and RPE65 reveal patterns of selective constraint across hereditary retinal disease mutations. ( 26750628 )
2016
31
Next-generation sequencing-based molecular diagnosis of 12 inherited retinal disease probands of Uyghur ethnicity. ( 26856745 )
2016
32
Vascular Endothelial Growth Factor and Diabetic Retinal Disease. ( 26959128 )
2016
33
Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease. ( 26881135 )
2016
34
Aging Changes in Retinal Microglia and their Relevance to Age-related Retinal Disease. ( 26427396 )
2016
35
Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier. ( 27664291 )
2016
36
Retinal disease in the C3 glomerulopathies and the risk of impaired vision. ( 26915021 )
2016
37
Cell therapy for retinal disease. ( 26859132 )
2016
38
Induced Pluripotent Stem Cells and Outer Retinal Disease. ( 26880948 )
2016
39
Elevated vitreous body glial fibrillary acidic protein in retinal diseases. ( 26279003 )
2015
40
Spatio-Temporal Signatures to Predict Retinal Disease Recurrence. ( 26221672 )
2015
41
Whole Exome Sequencing Reveals Mutations in Known Retinal Disease Genes in 33 out of 68 Israeli Families with Inherited Retinopathies. ( 26306921 )
2015
42
Prevalence of comorbid retinal disease in patients with glaucoma at an academic medical center. ( 26203217 )
2015
43
Hypoxia inducible factor single nucleotide polymorphisms: exploring the role of HIF polymorphisms in retinal disease. ( 25625895 )
2015
44
Identification of rod- and cone-specific expression signatures to identify candidate genes for retinal disease. ( 25579607 )
2015
45
Patient attitudes towards prenatal diagnostic testing for inherited retinal disease. ( 26126503 )
2015
46
Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency. ( 26233519 )
2015
47
Multimodal Imaging of Central Retinal Disease Progression in a 2-Year Mean Follow-up of Retinitis Pigmentosa. ( 26164827 )
2015
48
An introduction to OCT in retinal disease. ( 26828541 )
2015
49
Restoration of synaptic function in sight for degenerative retinal disease. ( 26098210 )
2015
50
Gene Therapy for Retinal Disease: What Lies Ahead. ( 26279067 )
2015

Variations for Retinal Disease

Expression for Retinal Disease

Search GEO for disease gene expression data for Retinal Disease.

Pathways for Retinal Disease

GO Terms for Retinal Disease

Cellular components related to Retinal Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 photoreceptor disc membrane GO:0097381 9.55 ABCA4 GUCA1A GUCY2D PDE6B RHO
2 photoreceptor inner segment GO:0001917 9.43 AIPL1 ARMS2 GUCA1A MYO7A RHO USH2A
3 photoreceptor outer segment GO:0001750 9.23 ABCA4 CACNA1F CNGB3 GUCA1A MYO7A PRPH2

Biological processes related to Retinal Disease according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.86 ABCA4 AIPL1 BEST1 CACNA1F CNGB3 CRX
2 retinoid metabolic process GO:0001523 9.67 ABCA4 RHO RPE65
3 retina development in camera-type eye GO:0060041 9.67 PDE6B PRPH2 RHO RPE65
4 retina homeostasis GO:0001895 9.65 AIPL1 ARMS2 RPE65
5 photoreceptor cell maintenance GO:0045494 9.63 ABCA4 RHO USH2A
6 detection of light stimulus involved in visual perception GO:0050908 9.58 BEST1 CACNA1F RPE65
7 regulation of rhodopsin mediated signaling pathway GO:0022400 9.56 GUCA1A GUCY2D PDE6B RHO
8 eye photoreceptor cell development GO:0042462 9.54 CRB1 MYO7A
9 rhodopsin mediated signaling pathway GO:0016056 9.52 PDE6B RHO
10 inner ear receptor cell differentiation GO:0060113 9.51 MYO7A USH2A
11 sensory perception of light stimulus GO:0050953 9.5 MYO7A RHO USH2A
12 response to stimulus GO:0050896 9.47 ABCA4 AIPL1 BEST1 CACNA1F CNGB3 CRX
13 phototransduction, visible light GO:0007603 9.46 ABCA4 AIPL1 PDE6B RHO
14 detection of light stimulus GO:0009583 9.43 PDE6B RHO

Sources for Retinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....